Twist Bioscience (TWST) Cost of Revenue (2017 - 2026)

Twist Bioscience (TWST) has reported Cost of Revenue for 10 consecutive years, with $55.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cost of Revenue rose 24.94% year-over-year to $55.9 million in Q2 2026; TTM through Jun 2026 was $207.4 million, a 12.8% increase from a year earlier, with the FY2025 full-year figure at $185.6 million, up 3.31% from the prior year.
• Cost of Revenue was $55.9 million for Q2 2026 at Twist Bioscience, up from $53.6 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $55.9 million in Q2 2026 and troughed at $29.4 million in Q4 2022.
• A 5-year average of $42.9 million and a median of $44.6 million in 2024 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue jumped 56.16% in 2022 and declined 3.1% in 2025, its largest moves.
• Over 5 years, Cost of Revenue stood at $29.4 million in 2022, then jumped by 44.47% to $42.5 million in 2023, then rose by 7.85% to $45.9 million in 2024, then increased by 8.4% to $49.7 million in 2025, then increased by 12.46% to $55.9 million in 2026.
• The last three Cost of Revenue figures came in at $55.9 million (Q2 2026), $53.6 million (Q1 2026), and $49.7 million (Q4 2025), per Business Quant data.